Minocycline mediated mitochondrial cytoprotection: Premises for therapy of cerebrovascular and neurodegenerative diseases

Current Drug Targets

Volumn 14, Issue 1, 2013, Pages 47-55

  Karachitos, Andonis ^a   del Pozo, Julian Solis García ^b   de Groot, Piet W J ^c   Kmita, Hanna ^a   Jordán, Joaquín ^c  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Cell death pathways; Cytoprotection; Energy coupling; Minocycline; Mitochondria; VDAC

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; CASPASE 3; CASPASE 8; CYCLOPHILIN D; CYTOCHROME C; MINOCYCLINE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; VOLTAGE DEPENDENT ANION CHANNEL 1; VOLTAGE DEPENDENT ANION CHANNEL 2; VOLTAGE DEPENDENT ANION CHANNEL 3;

APOPTOSIS; BRAIN DAMAGE; CELL PROTECTION; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; ENCEPHALITIS; EXCITOTOXICITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; MEMBRANE PERMEABILITY; MITOCHONDRION; MITOCHONDRION SWELLING; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW;

EID: 84876696944     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804806442     Document Type: Review

References (114)

1. Wood WG, Eckert GP, Igbavboa U, Muller WE. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 2010; 1199: 69-76.
2. Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep 2011; 63: 618-28.
3. Hamel E, Nicolakakis N, Aboulkassim T, Ongali B, Tong XK. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's's disease. Exp Physiol 2008; 93: 116-20.
4. Jordan J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008; 14: 3549-64.
5. Hazrati LN, Bergeron C, Butany J. Neuropathology of cerebrovascular diseases. Semin Diagn Pathol 2009; 26: 103-15.
6. Martin-Schild S, Hallevi H, Shaltoni H, et al. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia. J Stroke Cerebrovasc Dis 2009; 18: 86-96.
7. Jordan J, Ikuta I, Garcia-Garcia J, Calleja S, Segura T. Stroke pathophysiology: management challenges and new treatment advances. J Physiol Biochem 2007; 63: 261-77.
8. Segura T, Calleja S, Jordan J. Recommendations and treatment strategies for the management of acute ischemic stroke. Expert Opin Pharmacother 2008; 9: 1071-85.
9. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-19.
10. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
11. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-20.
12. Szczepanek K, Chen Q, Larner AC, Lesnefsky EJ. Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. Mitochondrion 2012; 12: 180-9.
13. Galindo MF, Ikuta I, Zhu X, Casadesus G, Jordan J. Mitochondrial biology in Alzheimer's's disease pathogenesis. J Neurochem 2010; 114: 933-45.
14. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 2007; 4: 225-31.
15. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004; 17: 359-66.
16. Antonenko YN, Rokitskaya TI, Cooper AJ, Krasnikov BF. Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels. J Bioenerg Biomembr 2010; 42: 151-63.
17. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol 2010; 79: 239-50.
18. Fernandez-Gomez FJ, Galindo MF, Gomez-Lazaro M, et al. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 2005; 133: 959-67.
19. Di Filippo M, Chiasserini D, Tozzi A, Picconi B, Calabresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimer's Dis 2010; 20 Suppl 2: S369-79.
20. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97: 1634-58.
21. Fatokun AA, Stone TW, Smith RA. Oxidative stress in neurodegeneration and available means of protection. Front Biosci 2008; 13: 3288-311.
22. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999; 96: 13496-500.
23. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001; 909: 187-93.
24. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001; 21: 2580-8.
25. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801.
26. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-8.
27. Beresford IJ, Parsons AA, Hunter AJ. Treatments for stroke. Expert Opin Emerg Drugs 2003; 8: 103-22.
28. Yuan J, Lipinski M, Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron 2003; 40: 401-13.
29. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009; 15: 89-100.
30. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010; 460: 525-42.
31. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004; 36: 257-64.
32. Pivovarova NB, Andrews SB. Calcium-dependent mitochondrial function and dysfunction in neurons. FEBS J 2010; 277: 3622-36.
33. Nicholls DG. Oxidative stress and energy crises in neuronal dysfunction. Ann N Y Acad Sci 2008; 1147: 53-60.
34. Bernardi P, Krauskopf A, Basso E, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J 2006; 273: 2077-99.
35. Jemmerson R, Dubinsky JM, Brustovetsky N. Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases. Antioxid Redox Signal 2005; 7: 1158-72.
36. Grohm J, Plesnila N, Culmsee C. Bid mediates fission, membrane permeabilization and peri-nuclear accumulation of mitochondria as a prerequisite for oxidative neuronal cell death. Brain Behav Immun 2010; 24: 831-8.
37. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007; 54: 34-66.
38. Forder JP, Tymianski M. Postsynaptic mechanisms of excitotoxicity: Involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience 2009; 158: 293-300.
39. Khodorov B. Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones. Prog Biophys Mol Biol 2004; 86: 279-351.
40. Gonzalez JC, Egea J, Del Carmen Godino M, et al. Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. Eur J Neurosci 2007; 26: 2481-95.
41. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab 2011; 31: 1003-19.
42. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005; 94: 819-27.
43. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342-57.
44. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135: 1161-3.
45. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-32.
46. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. Viral control of mitochondrial apoptosis. PLoS Pathog 2008; 4: e1000018.
47. Rehm M, Huber HJ, Hellwig CT, Anguissola S, Dussmann H, Prehn JH. Dynamics of outer mitochondrial membrane permeabilization during apoptosis. Cell Death Differ 2009; 16: 613-23.
48. Kushnareva Y, Newmeyer DD. Bioenergetics and cell death. Ann N Y Acad Sci 2010; 1201: 50-7.
49. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 2010; 31: 227-85.
50. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009; 46: 821-31.
51. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007; 67: 5999-6002.
52. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 2009; 83: 213-25.
53. Galindo MF, Jordan J, Gonzalez-Garcia C, Cena V. Reactive oxygen species induce swelling and cytochrome c release but not transmembrane depolarization in isolated rat brain mitochondria. Br J Pharmacol 2003; 139: 797-804.
54. Galindo MF, Jordan J, Gonzalez-Garcia C, Cena V. Chromaffin cell death induced by 6-hydroxydopamine is independent of mitochondrial swelling and caspase activation. J Neurochem 2003; 84: 1066-73.
55. Peixoto PM, Dejean LM, Kinnally KW. The therapeutic potential of mitochondrial channels in cancer, ischemia-reperfusion injury, and neurodegeneration. Mitochondrion 2012; 12: 14-23.
56. Varanyuwatana P, Halestrap AP. The roles of phosphate and the phosphate carrier in the mitochondrial permeability transition pore. Mitochondrion 2012; 12: 120-5.
57. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-9.
58. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 2006; 34: 232-7.
59. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84: 153-66.
60. Mannella CA, Pfeiffer DR, Bradshaw PC, et al. Topology of the mitochondrial inner membrane: dynamics and bioenergetic implications. IUBMB Life 2001; 52: 93-100.
61. Gao W, Pu Y, Luo KQ, Chang DC. Temporal relationship between cytochrome c release and mitochondrial swelling during UVinduced apoptosis in living HeLa cells. J Cell Sci 2001; 114: 2855-62.
62. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 2009; 10: 481-94.
63. Wang CX, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol 2002; 2: 2.
64. Cornet S, Spinnewyn B, Delaflotte S, et al. Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline. Eur J Pharmacol 2004; 505: 111-9.
65. Skulachev VP. Mitochondrial physiology and pathology; concepts of programmed death of organelles, cells and organisms. Mol Aspects Med 1999; 20: 139-84.
66. Kupsch K, Hertel S, Kreutzmann P, et al. Impairment of mitochondrial function by minocycline. FEBS J 2009; 276: 1729-38.
67. Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E. Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis 2007; 25: 198-205.
68. Gieseler A, Schultze AT, Kupsch K, et al. Inhibitory modulation of the mitochondrial permeability transition by minocycline. Biochem Pharmacol 2009; 77: 888-96.
69. Cuenca-Lopez MD, Karachitos A, Massarotto L, et al. Minocycline exerts uncoupling and inhibiting effects on mitochondrial respiration through adenine nucleotide translocase inhibition. Pharmacol Res 2012; 65: 120-8.
70. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53.
71. Mannella CA, Kinnally KW. Reflections on VDAC as a voltagegated channel and a mitochondrial regulator. J Bioenerg Biomembr 2008; 40: 149-55.
72. Rostovtseva TK, Bezrukov SM. VDAC regulation: role of cytosolic proteins and mitochondrial lipids. J Bioenerg Biomembr 2008; 40: 163-70.
73. Lemasters JJ, Holmuhamedov E. Voltage-dependent anion channel (VDAC) as mitochondrial governator--thinking outside the box. Biochim Biophys Acta 2006; 1762: 181-90.
74. Schein SJ, Colombini M, Finkelstein A. Reconstitution in planar lipid bilayers of a voltage-dependent anion-selective channel obtained from paramecium mitochondria. J Membr Biol 1976; 30: 99-120.
75. Benz R. Permeation of hydrophilic solutes through mitochondrial outer membranes: review on mitochondrial porins. Biochim Biophys Acta 1994; 1197: 167-96.
76. Blachly-Dyson E, Forte M. VDAC channels. IUBMB Life 2001; 52: 113-8.
77. De Pinto V, Messina A, Accardi R, et al. New functions of an old protein: the eukaryotic porin or voltage dependent anion selective channel (VDAC). Ital J Biochem 2003; 52: 17-24.
78. Colombini M. VDAC: the channel at the interface between mitochondria and the cytosol. Mol Cell Biochem 2004; 256-257: 107-15.
79. Shoshan-Barmatz V, Keinan N, Zaid H. Uncovering the role of VDAC in the regulation of cell life and death. J Bioenerg Biomembr 2008; 40: 183-91.
80. McCommis KS, Baines CP. The role of VDAC in cell death: Friend or foe? Biochim Biophys Acta 2012; 1818: 1444-50.
81. Messina A, Reina S, Guarino F, De Pinto V. VDAC isoforms in mammals. Biochim Biophys Acta 2012; 1818: 1466-76.
82. De Stefani D, Bononi A, Romagnoli A, et al. VDAC1 selectively transfers apoptotic Ca2+ signals to mitochondria. Cell Death Differ 2012; 19: 267-73.
83. Galganska H, Antoniewicz M, Budzinska M, Galganski L, Kmita H. VDAC contributes to mRNA levels in Saccharomyces cerevisiae cells by the intracellular reduction/oxidation state dependent and independent mechanisms. J Bioenerg Biomembr 2010; 42: 483-9.
84. Galganska H, Karachitos A, Wojtkowska M, Stobienia O, Budzinska M, Kmita H. Communication between mitochondria and nucleus: Putative role for VDAC in reduction/oxidation mechanism. Biochim Biophys Acta 2010; 1797: 1276-80.
85. Galganska H, Budzinska M, Wojtkowska M, Kmita H. Redox regulation of protein expression in Saccharomyces cerevisiae mitochondria: possible role of VDAC. Arch Biochem Biophys 2008; 479: 39-45.
86. Han D, Antunes F, Canali R, Rettori D, Cadenas E. Voltagedependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem 2003; 278: 5557-63.
87. Allen JF. The function of genomes in bioenergetic organelles. Philos Trans R Soc Lond B Biol Sci 2003; 358: 19-37; discussion-8.
88. Butow RA, Avadhani NG. Mitochondrial signaling: the retrograde response. Mol Cell 2004; 14: 1-15.
89. Liu H, Colavitti R, Rovira, II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005; 97: 967-74.
90. Storz P. Reactive oxygen species-mediated mitochondria-tonucleus signaling: a key to aging and radical-caused diseases. Sci STKE 2006; 2006: re3.
91. Pesaresi P, Schneider A, Kleine T, Leister D. Interorganellar communication. Curr Opin Plant Biol 2007; 10: 600-6.
92. Woodson JD, Chory J. Coordination of gene expression between organellar and nuclear genomes. Nat Rev Genet 2008; 9: 383-95.
93. Cannino G, Di Liegro CM, Rinaldi AM. Nuclear-mitochondrial interaction. Mitochondrion 2007; 7: 359-66.
94. Duchen MR. Roles of mitochondria in health and disease. Diabetes 2004; 53 Suppl 1: S96-102.
95. Monsalve M, Borniquel S, Valle I, Lamas S. Mitochondrial dysfunction in human pathologies. Front Biosci 2007; 12: 1131-53.
96. Wawryn J, Swiecilo A, Bartosz G, Bilinski T. Effect of superoxide dismutase deficiency on the life span of the yeast Saccharomyces cerevisiae. An oxygen-independent role of Cu, Zn-superoxide dismutase. Biochim Biophys Acta 2002; 1570: 199-202.
97. O'Brien KM, Dirmeier R, Engle M, Poyton RO. Mitochondrial protein oxidation in yeast mutants lacking manganese-(MnSOD) or copper-and zinc-containing superoxide dismutase (CuZnSOD): evidence that MnSOD and CuZnSOD have both unique and overlapping functions in protecting mitochondrial proteins from oxidative damage. J Biol Chem 2004; 279: 51817-27.
98. Elchuri S, Oberley TD, Qi W, et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 2005; 24: 367-80.
99. Karachitos A, Galganska H, Wojtkowska M, et al. Cu, Znsuperoxide dismutase is necessary for proper function of VDAC in Saccharomyces cerevisiae cells. FEBS Lett 2009; 583: 449-55.
100. De Pinto V, Messina A, Schmid A, Simonetti S, Carnevale F, Benz R. Characterization of channel-forming activity in muscle biopsy from a porin-deficient human patient. J Bioenerg Biomembr 2000; 32: 585-93.
101. Huizing M, Ruitenbeek W, Thinnes FP, et al. Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy. Pediatr Res 1996; 39: 760-5.
102. Martin LJ. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006; 65: 1103-10.
103. Ferrer I. Altered mitochondria, energy metabolism, voltagedependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009; 41: 425-31.
104. Jonas EA. Molecular participants in mitochondrial cell death channel formation during neuronal ischemia. Exp Neurol 2009; 218: 203-12.
105. Kumarswamy R, Chandna S. Putative partners in Bax mediated cytochrome-c release: ANT, CypD, VDAC or none of them? Mitochondrion 2009; 9: 1-8.
106. Bonanni L, Chachar M, Jover-Mengual T, et al. Zinc-dependent multi-conductance channel activity in mitochondria isolated from ischemic brain. J Neurosci 2006; 26: 6851-62.
107. Perez Velazquez JL, Kokarovtseva L, Weisspapir M, Frantseva MV. Anti-porin antibodies prevent excitotoxic and ischemic damage to brain tissue. J Neurotrauma 2003; 20: 633-47.
108. Shoshan-Barmatz V, Ben-Hail D. VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion 2012; 12: 24-34.
109. Tan W, Loke YH, Stein CA, Miller P, Colombini M. Phosphorothioate oligonucleotides block the VDAC channel. Biophys J 2007; 93: 1184-91.
110. Galganska H, Karachitos A, Baranek M, Budzinska M, Jordan J, Kmita H. Viability of Saccharomyces cerevisiae cells following exposure to H2O2 and protective effect of minocycline depend on the presence of VDAC. Eur J Pharmacol 2010; 643: 42-7.
111. Karachitos A, Jordan J, Kmita H. Cytoprotective activity of minocycline includes improvement of mitochondrial coupling: the importance of minocycline concentration and the presence of VDAC. J Bioenerg Biomembr 2012; 44: 297-307.
112. Michejda J, Guo XJ, Lauquin GJ. The respiration of cells and mitochondria of porin deficient yeast mutants is coupled. Biochem Biophys Res Commun 1990; 171: 354-61.
113. Mansson R, Morota S, Hansson MJ, et al. Minocycline sensitizes rodent and human liver mitochondria to the permeability transition: implications for toxicity in liver transplantation. Hepatology 2010; 51: 347-8; author reply 9-50.
114. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-10.